nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Ezetimibe—atherosclerosis	0.0854	0.152	CbGbCtD
Dihydroergotamine—ABCB1—Simvastatin—atherosclerosis	0.0794	0.141	CbGbCtD
Dihydroergotamine—ABCB1—Lovastatin—atherosclerosis	0.0777	0.138	CbGbCtD
Dihydroergotamine—ABCB1—Pravastatin—atherosclerosis	0.0777	0.138	CbGbCtD
Dihydroergotamine—CYP3A4—Ezetimibe—atherosclerosis	0.0512	0.0909	CbGbCtD
Dihydroergotamine—CYP3A4—Rosuvastatin—atherosclerosis	0.0512	0.0909	CbGbCtD
Dihydroergotamine—CYP3A4—Simvastatin—atherosclerosis	0.0476	0.0845	CbGbCtD
Dihydroergotamine—CYP3A4—Lovastatin—atherosclerosis	0.0466	0.0827	CbGbCtD
Dihydroergotamine—CYP3A4—Pravastatin—atherosclerosis	0.0466	0.0827	CbGbCtD
Dihydroergotamine—Bronchitis—Rosuvastatin—atherosclerosis	0.00207	0.00739	CcSEcCtD
Dihydroergotamine—Injury—Pravastatin—atherosclerosis	0.00194	0.00693	CcSEcCtD
Dihydroergotamine—Hot flush—Pravastatin—atherosclerosis	0.00191	0.00681	CcSEcCtD
Dihydroergotamine—Cramp muscle—Lovastatin—atherosclerosis	0.0019	0.00678	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Pravastatin—atherosclerosis	0.00189	0.00675	CcSEcCtD
Dihydroergotamine—Cramp muscle—Ezetimibe—atherosclerosis	0.00186	0.00665	CcSEcCtD
Dihydroergotamine—Muscular weakness—Ezetimibe—atherosclerosis	0.00182	0.00652	CcSEcCtD
Dihydroergotamine—Sinusitis—Rosuvastatin—atherosclerosis	0.0018	0.00643	CcSEcCtD
Dihydroergotamine—Migraine—Niacin—atherosclerosis	0.00178	0.00637	CcSEcCtD
Dihydroergotamine—Cramp muscle—Simvastatin—atherosclerosis	0.00178	0.00635	CcSEcCtD
Dihydroergotamine—Face oedema—Niacin—atherosclerosis	0.00175	0.00625	CcSEcCtD
Dihydroergotamine—Muscular weakness—Simvastatin—atherosclerosis	0.00174	0.00621	CcSEcCtD
Dihydroergotamine—Rhinitis—Rosuvastatin—atherosclerosis	0.00173	0.00617	CcSEcCtD
Dihydroergotamine—Pharyngitis—Rosuvastatin—atherosclerosis	0.00171	0.0061	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00166	0.00594	CcSEcCtD
Dihydroergotamine—Bronchitis—Simvastatin—atherosclerosis	0.00164	0.00586	CcSEcCtD
Dihydroergotamine—Cramp muscle—Pravastatin—atherosclerosis	0.00161	0.00574	CcSEcCtD
Dihydroergotamine—Muscular weakness—Niacin—atherosclerosis	0.0016	0.00571	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00158	0.00566	CcSEcCtD
Dihydroergotamine—Muscular weakness—Pravastatin—atherosclerosis	0.00157	0.00562	CcSEcCtD
Dihydroergotamine—Dysphagia—Niacin—atherosclerosis	0.00157	0.00559	CcSEcCtD
Dihydroergotamine—Angina pectoris—Niacin—atherosclerosis	0.00152	0.00545	CcSEcCtD
Dihydroergotamine—Sinusitis—Lovastatin—atherosclerosis	0.00152	0.00545	CcSEcCtD
Dihydroergotamine—Bronchitis—Niacin—atherosclerosis	0.00151	0.00538	CcSEcCtD
Dihydroergotamine—Sweating increased—Pravastatin—atherosclerosis	0.0015	0.00536	CcSEcCtD
Dihydroergotamine—Angina pectoris—Pravastatin—atherosclerosis	0.0015	0.00536	CcSEcCtD
Dihydroergotamine—Sinusitis—Ezetimibe—atherosclerosis	0.0015	0.00534	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00143	0.00512	CcSEcCtD
Dihydroergotamine—Sinusitis—Simvastatin—atherosclerosis	0.00143	0.00509	CcSEcCtD
Dihydroergotamine—Pharyngitis—Ezetimibe—atherosclerosis	0.00142	0.00507	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00135	0.00484	CcSEcCtD
Dihydroergotamine—Flushing—Lovastatin—atherosclerosis	0.00135	0.00484	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Pravastatin—atherosclerosis	0.00135	0.00481	CcSEcCtD
Dihydroergotamine—Flushing—Ezetimibe—atherosclerosis	0.00133	0.00474	CcSEcCtD
Dihydroergotamine—Chills—Lovastatin—atherosclerosis	0.00131	0.00468	CcSEcCtD
Dihydroergotamine—Sinusitis—Pravastatin—atherosclerosis	0.00129	0.00461	CcSEcCtD
Dihydroergotamine—Arthralgia—Rosuvastatin—atherosclerosis	0.00128	0.00456	CcSEcCtD
Dihydroergotamine—Myalgia—Rosuvastatin—atherosclerosis	0.00128	0.00456	CcSEcCtD
Dihydroergotamine—Flushing—Simvastatin—atherosclerosis	0.00127	0.00452	CcSEcCtD
Dihydroergotamine—Rhinitis—Niacin—atherosclerosis	0.00126	0.00449	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Niacin—atherosclerosis	0.00125	0.00445	CcSEcCtD
Dihydroergotamine—Rhinitis—Pravastatin—atherosclerosis	0.00124	0.00442	CcSEcCtD
Dihydroergotamine—Confusional state—Rosuvastatin—atherosclerosis	0.00123	0.00441	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Pravastatin—atherosclerosis	0.00123	0.00439	CcSEcCtD
Dihydroergotamine—Pharyngitis—Pravastatin—atherosclerosis	0.00122	0.00437	CcSEcCtD
Dihydroergotamine—Chills—Simvastatin—atherosclerosis	0.00122	0.00437	CcSEcCtD
Dihydroergotamine—Muscle spasms—Lovastatin—atherosclerosis	0.00122	0.00436	CcSEcCtD
Dihydroergotamine—Visual impairment—Niacin—atherosclerosis	0.00121	0.00431	CcSEcCtD
Dihydroergotamine—Muscle spasms—Ezetimibe—atherosclerosis	0.0012	0.00428	CcSEcCtD
Dihydroergotamine—Tremor—Lovastatin—atherosclerosis	0.00119	0.00425	CcSEcCtD
Dihydroergotamine—Visual impairment—Pravastatin—atherosclerosis	0.00119	0.00425	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Lovastatin—atherosclerosis	0.00118	0.00421	CcSEcCtD
Dihydroergotamine—Tinnitus—Niacin—atherosclerosis	0.00117	0.00417	CcSEcCtD
Dihydroergotamine—Flushing—Niacin—atherosclerosis	0.00116	0.00415	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00116	0.00413	CcSEcCtD
Dihydroergotamine—Tinnitus—Pravastatin—atherosclerosis	0.00115	0.00411	CcSEcCtD
Dihydroergotamine—Malaise—Lovastatin—atherosclerosis	0.00115	0.00409	CcSEcCtD
Dihydroergotamine—Flushing—Pravastatin—atherosclerosis	0.00114	0.00409	CcSEcCtD
Dihydroergotamine—Muscle spasms—Simvastatin—atherosclerosis	0.00114	0.00408	CcSEcCtD
Dihydroergotamine—Vertigo—Lovastatin—atherosclerosis	0.00114	0.00408	CcSEcCtD
Dihydroergotamine—Chills—Niacin—atherosclerosis	0.00112	0.00402	CcSEcCtD
Dihydroergotamine—Malaise—Ezetimibe—atherosclerosis	0.00112	0.00401	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00111	0.00398	CcSEcCtD
Dihydroergotamine—Tremor—Simvastatin—atherosclerosis	0.00111	0.00398	CcSEcCtD
Dihydroergotamine—Chills—Pravastatin—atherosclerosis	0.00111	0.00395	CcSEcCtD
Dihydroergotamine—Insomnia—Rosuvastatin—atherosclerosis	0.00111	0.00395	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Simvastatin—atherosclerosis	0.0011	0.00394	CcSEcCtD
Dihydroergotamine—Palpitations—Ezetimibe—atherosclerosis	0.0011	0.00393	CcSEcCtD
Dihydroergotamine—Paraesthesia—Rosuvastatin—atherosclerosis	0.0011	0.00392	CcSEcCtD
Dihydroergotamine—Myalgia—Lovastatin—atherosclerosis	0.00108	0.00386	CcSEcCtD
Dihydroergotamine—Arthralgia—Lovastatin—atherosclerosis	0.00108	0.00386	CcSEcCtD
Dihydroergotamine—Anxiety—Lovastatin—atherosclerosis	0.00108	0.00385	CcSEcCtD
Dihydroergotamine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00108	0.00385	CcSEcCtD
Dihydroergotamine—Hypertension—Ezetimibe—atherosclerosis	0.00108	0.00384	CcSEcCtD
Dihydroergotamine—Malaise—Simvastatin—atherosclerosis	0.00107	0.00383	CcSEcCtD
Dihydroergotamine—Tension—Niacin—atherosclerosis	0.00107	0.00382	CcSEcCtD
Dihydroergotamine—Discomfort—Lovastatin—atherosclerosis	0.00107	0.00382	CcSEcCtD
Dihydroergotamine—Vertigo—Simvastatin—atherosclerosis	0.00107	0.00381	CcSEcCtD
Dihydroergotamine—Myalgia—Ezetimibe—atherosclerosis	0.00106	0.00379	CcSEcCtD
Dihydroergotamine—Arthralgia—Ezetimibe—atherosclerosis	0.00106	0.00379	CcSEcCtD
Dihydroergotamine—Nervousness—Niacin—atherosclerosis	0.00106	0.00378	CcSEcCtD
Dihydroergotamine—Dry mouth—Lovastatin—atherosclerosis	0.00106	0.00378	CcSEcCtD
Dihydroergotamine—Tension—Pravastatin—atherosclerosis	0.00105	0.00376	CcSEcCtD
Dihydroergotamine—Muscle spasms—Niacin—atherosclerosis	0.00105	0.00375	CcSEcCtD
Dihydroergotamine—Discomfort—Ezetimibe—atherosclerosis	0.00105	0.00374	CcSEcCtD
Dihydroergotamine—Pain—Rosuvastatin—atherosclerosis	0.00105	0.00374	CcSEcCtD
Dihydroergotamine—Confusional state—Lovastatin—atherosclerosis	0.00105	0.00373	CcSEcCtD
Dihydroergotamine—Nervousness—Pravastatin—atherosclerosis	0.00104	0.00373	CcSEcCtD
Dihydroergotamine—Dry mouth—Ezetimibe—atherosclerosis	0.00104	0.0037	CcSEcCtD
Dihydroergotamine—Muscle spasms—Pravastatin—atherosclerosis	0.00103	0.00369	CcSEcCtD
Dihydroergotamine—Confusional state—Ezetimibe—atherosclerosis	0.00102	0.00366	CcSEcCtD
Dihydroergotamine—Arthralgia—Simvastatin—atherosclerosis	0.00101	0.00361	CcSEcCtD
Dihydroergotamine—Myalgia—Simvastatin—atherosclerosis	0.00101	0.00361	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00101	0.0036	CcSEcCtD
Dihydroergotamine—Anxiety—Simvastatin—atherosclerosis	0.00101	0.0036	CcSEcCtD
Dihydroergotamine—Tremor—Pravastatin—atherosclerosis	0.00101	0.00359	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.001	0.00357	CcSEcCtD
Dihydroergotamine—Discomfort—Simvastatin—atherosclerosis	0.000999	0.00357	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000996	0.00356	CcSEcCtD
Dihydroergotamine—Anorexia—Lovastatin—atherosclerosis	0.000988	0.00353	CcSEcCtD
Dihydroergotamine—Vertigo—Niacin—atherosclerosis	0.00098	0.0035	CcSEcCtD
Dihydroergotamine—Confusional state—Simvastatin—atherosclerosis	0.000977	0.00349	CcSEcCtD
Dihydroergotamine—Urticaria—Rosuvastatin—atherosclerosis	0.000972	0.00347	CcSEcCtD
Dihydroergotamine—Oedema—Simvastatin—atherosclerosis	0.000969	0.00346	CcSEcCtD
Dihydroergotamine—Malaise—Pravastatin—atherosclerosis	0.000968	0.00346	CcSEcCtD
Dihydroergotamine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000967	0.00345	CcSEcCtD
Dihydroergotamine—Vertigo—Pravastatin—atherosclerosis	0.000965	0.00345	CcSEcCtD
Dihydroergotamine—Palpitations—Niacin—atherosclerosis	0.000964	0.00344	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000944	0.00337	CcSEcCtD
Dihydroergotamine—Insomnia—Lovastatin—atherosclerosis	0.000937	0.00335	CcSEcCtD
Dihydroergotamine—Paraesthesia—Lovastatin—atherosclerosis	0.000931	0.00332	CcSEcCtD
Dihydroergotamine—Arthralgia—Niacin—atherosclerosis	0.000929	0.00332	CcSEcCtD
Dihydroergotamine—Myalgia—Niacin—atherosclerosis	0.000929	0.00332	CcSEcCtD
Dihydroergotamine—Hypertension—Pravastatin—atherosclerosis	0.000927	0.00331	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000926	0.00331	CcSEcCtD
Dihydroergotamine—Anorexia—Simvastatin—atherosclerosis	0.000924	0.0033	CcSEcCtD
Dihydroergotamine—Dyspnoea—Lovastatin—atherosclerosis	0.000924	0.0033	CcSEcCtD
Dihydroergotamine—Insomnia—Ezetimibe—atherosclerosis	0.000919	0.00328	CcSEcCtD
Dihydroergotamine—Arthralgia—Pravastatin—atherosclerosis	0.000914	0.00327	CcSEcCtD
Dihydroergotamine—Myalgia—Pravastatin—atherosclerosis	0.000914	0.00327	CcSEcCtD
Dihydroergotamine—Paraesthesia—Ezetimibe—atherosclerosis	0.000913	0.00326	CcSEcCtD
Dihydroergotamine—Dyspepsia—Lovastatin—atherosclerosis	0.000912	0.00326	CcSEcCtD
Dihydroergotamine—Anxiety—Pravastatin—atherosclerosis	0.000911	0.00325	CcSEcCtD
Dihydroergotamine—Dry mouth—Niacin—atherosclerosis	0.000908	0.00324	CcSEcCtD
Dihydroergotamine—Dyspnoea—Ezetimibe—atherosclerosis	0.000906	0.00324	CcSEcCtD
Dihydroergotamine—Discomfort—Pravastatin—atherosclerosis	0.000903	0.00323	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000901	0.00322	CcSEcCtD
Dihydroergotamine—Decreased appetite—Lovastatin—atherosclerosis	0.000901	0.00322	CcSEcCtD
Dihydroergotamine—Dyspepsia—Ezetimibe—atherosclerosis	0.000895	0.0032	CcSEcCtD
Dihydroergotamine—Fatigue—Lovastatin—atherosclerosis	0.000894	0.00319	CcSEcCtD
Dihydroergotamine—Oedema—Niacin—atherosclerosis	0.00089	0.00318	CcSEcCtD
Dihydroergotamine—Pain—Lovastatin—atherosclerosis	0.000886	0.00317	CcSEcCtD
Dihydroergotamine—Confusional state—Pravastatin—atherosclerosis	0.000884	0.00316	CcSEcCtD
Dihydroergotamine—Decreased appetite—Ezetimibe—atherosclerosis	0.000884	0.00316	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000883	0.00316	CcSEcCtD
Dihydroergotamine—Asthenia—Rosuvastatin—atherosclerosis	0.000877	0.00313	CcSEcCtD
Dihydroergotamine—Insomnia—Simvastatin—atherosclerosis	0.000877	0.00313	CcSEcCtD
Dihydroergotamine—Oedema—Pravastatin—atherosclerosis	0.000876	0.00313	CcSEcCtD
Dihydroergotamine—Fatigue—Ezetimibe—atherosclerosis	0.000876	0.00313	CcSEcCtD
Dihydroergotamine—Shock—Niacin—atherosclerosis	0.000876	0.00313	CcSEcCtD
Dihydroergotamine—Paraesthesia—Simvastatin—atherosclerosis	0.00087	0.00311	CcSEcCtD
Dihydroergotamine—Pain—Ezetimibe—atherosclerosis	0.000869	0.00311	CcSEcCtD
Dihydroergotamine—Tachycardia—Niacin—atherosclerosis	0.000869	0.0031	CcSEcCtD
Dihydroergotamine—Pruritus—Rosuvastatin—atherosclerosis	0.000865	0.00309	CcSEcCtD
Dihydroergotamine—Dyspnoea—Simvastatin—atherosclerosis	0.000864	0.00309	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Niacin—atherosclerosis	0.000861	0.00307	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Lovastatin—atherosclerosis	0.000854	0.00305	CcSEcCtD
Dihydroergotamine—Dyspepsia—Simvastatin—atherosclerosis	0.000853	0.00305	CcSEcCtD
Dihydroergotamine—Anorexia—Niacin—atherosclerosis	0.000848	0.00303	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000847	0.00303	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000847	0.00303	CcSEcCtD
Dihydroergotamine—Decreased appetite—Simvastatin—atherosclerosis	0.000843	0.00301	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000838	0.00299	CcSEcCtD
Dihydroergotamine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000837	0.00299	CcSEcCtD
Dihydroergotamine—Fatigue—Simvastatin—atherosclerosis	0.000836	0.00299	CcSEcCtD
Dihydroergotamine—Anorexia—Pravastatin—atherosclerosis	0.000835	0.00298	CcSEcCtD
Dihydroergotamine—Hypotension—Niacin—atherosclerosis	0.000832	0.00297	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000831	0.00297	CcSEcCtD
Dihydroergotamine—Pain—Simvastatin—atherosclerosis	0.000829	0.00296	CcSEcCtD
Dihydroergotamine—Urticaria—Lovastatin—atherosclerosis	0.000823	0.00294	CcSEcCtD
Dihydroergotamine—Abdominal pain—Lovastatin—atherosclerosis	0.000819	0.00293	CcSEcCtD
Dihydroergotamine—Body temperature increased—Lovastatin—atherosclerosis	0.000819	0.00293	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000811	0.0029	CcSEcCtD
Dihydroergotamine—Dizziness—Rosuvastatin—atherosclerosis	0.000809	0.00289	CcSEcCtD
Dihydroergotamine—Urticaria—Ezetimibe—atherosclerosis	0.000808	0.00289	CcSEcCtD
Dihydroergotamine—Insomnia—Niacin—atherosclerosis	0.000805	0.00288	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ezetimibe—atherosclerosis	0.000804	0.00287	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ezetimibe—atherosclerosis	0.000804	0.00287	CcSEcCtD
Dihydroergotamine—Paraesthesia—Niacin—atherosclerosis	0.000799	0.00286	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Simvastatin—atherosclerosis	0.000799	0.00285	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000798	0.00285	CcSEcCtD
Dihydroergotamine—Dyspnoea—Niacin—atherosclerosis	0.000794	0.00284	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000793	0.00283	CcSEcCtD
Dihydroergotamine—Insomnia—Pravastatin—atherosclerosis	0.000793	0.00283	CcSEcCtD
Dihydroergotamine—Somnolence—Niacin—atherosclerosis	0.000791	0.00283	CcSEcCtD
Dihydroergotamine—Paraesthesia—Pravastatin—atherosclerosis	0.000787	0.00281	CcSEcCtD
Dihydroergotamine—Dyspepsia—Niacin—atherosclerosis	0.000784	0.0028	CcSEcCtD
Dihydroergotamine—Dyspnoea—Pravastatin—atherosclerosis	0.000781	0.00279	CcSEcCtD
Dihydroergotamine—Decreased appetite—Niacin—atherosclerosis	0.000774	0.00276	CcSEcCtD
Dihydroergotamine—Dyspepsia—Pravastatin—atherosclerosis	0.000771	0.00276	CcSEcCtD
Dihydroergotamine—Rash—Rosuvastatin—atherosclerosis	0.000771	0.00275	CcSEcCtD
Dihydroergotamine—Dermatitis—Rosuvastatin—atherosclerosis	0.00077	0.00275	CcSEcCtD
Dihydroergotamine—Urticaria—Simvastatin—atherosclerosis	0.00077	0.00275	CcSEcCtD
Dihydroergotamine—Abdominal pain—Simvastatin—atherosclerosis	0.000766	0.00274	CcSEcCtD
Dihydroergotamine—Body temperature increased—Simvastatin—atherosclerosis	0.000766	0.00274	CcSEcCtD
Dihydroergotamine—Headache—Rosuvastatin—atherosclerosis	0.000766	0.00274	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Lovastatin—atherosclerosis	0.000764	0.00273	CcSEcCtD
Dihydroergotamine—Decreased appetite—Pravastatin—atherosclerosis	0.000762	0.00272	CcSEcCtD
Dihydroergotamine—Pain—Niacin—atherosclerosis	0.000761	0.00272	CcSEcCtD
Dihydroergotamine—Fatigue—Pravastatin—atherosclerosis	0.000756	0.0027	CcSEcCtD
Dihydroergotamine—Pain—Pravastatin—atherosclerosis	0.000749	0.00268	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000749	0.00268	CcSEcCtD
Dihydroergotamine—Asthenia—Lovastatin—atherosclerosis	0.000744	0.00266	CcSEcCtD
Dihydroergotamine—Pruritus—Lovastatin—atherosclerosis	0.000733	0.00262	CcSEcCtD
Dihydroergotamine—Asthenia—Ezetimibe—atherosclerosis	0.000729	0.00261	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Niacin—atherosclerosis	0.000728	0.0026	CcSEcCtD
Dihydroergotamine—Nausea—Rosuvastatin—atherosclerosis	0.000726	0.0026	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Pravastatin—atherosclerosis	0.000722	0.00258	CcSEcCtD
Dihydroergotamine—Pruritus—Ezetimibe—atherosclerosis	0.000719	0.00257	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000717	0.00256	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Simvastatin—atherosclerosis	0.000714	0.00255	CcSEcCtD
Dihydroergotamine—Diarrhoea—Lovastatin—atherosclerosis	0.000709	0.00253	CcSEcCtD
Dihydroergotamine—Urticaria—Niacin—atherosclerosis	0.000707	0.00253	CcSEcCtD
Dihydroergotamine—Body temperature increased—Niacin—atherosclerosis	0.000704	0.00251	CcSEcCtD
Dihydroergotamine—Abdominal pain—Niacin—atherosclerosis	0.000704	0.00251	CcSEcCtD
Dihydroergotamine—Urticaria—Pravastatin—atherosclerosis	0.000696	0.00249	CcSEcCtD
Dihydroergotamine—Asthenia—Simvastatin—atherosclerosis	0.000696	0.00248	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ezetimibe—atherosclerosis	0.000696	0.00248	CcSEcCtD
Dihydroergotamine—Body temperature increased—Pravastatin—atherosclerosis	0.000693	0.00248	CcSEcCtD
Dihydroergotamine—Abdominal pain—Pravastatin—atherosclerosis	0.000693	0.00248	CcSEcCtD
Dihydroergotamine—Pruritus—Simvastatin—atherosclerosis	0.000686	0.00245	CcSEcCtD
Dihydroergotamine—Dizziness—Lovastatin—atherosclerosis	0.000685	0.00245	CcSEcCtD
Dihydroergotamine—Dizziness—Ezetimibe—atherosclerosis	0.000672	0.0024	CcSEcCtD
Dihydroergotamine—Diarrhoea—Simvastatin—atherosclerosis	0.000663	0.00237	CcSEcCtD
Dihydroergotamine—Vomiting—Lovastatin—atherosclerosis	0.000659	0.00235	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Niacin—atherosclerosis	0.000656	0.00234	CcSEcCtD
Dihydroergotamine—Rash—Lovastatin—atherosclerosis	0.000653	0.00233	CcSEcCtD
Dihydroergotamine—Dermatitis—Lovastatin—atherosclerosis	0.000653	0.00233	CcSEcCtD
Dihydroergotamine—Headache—Lovastatin—atherosclerosis	0.000649	0.00232	CcSEcCtD
Dihydroergotamine—Vomiting—Ezetimibe—atherosclerosis	0.000646	0.00231	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Pravastatin—atherosclerosis	0.000646	0.00231	CcSEcCtD
Dihydroergotamine—Dizziness—Simvastatin—atherosclerosis	0.000641	0.00229	CcSEcCtD
Dihydroergotamine—Rash—Ezetimibe—atherosclerosis	0.000641	0.00229	CcSEcCtD
Dihydroergotamine—Dermatitis—Ezetimibe—atherosclerosis	0.00064	0.00229	CcSEcCtD
Dihydroergotamine—Asthenia—Niacin—atherosclerosis	0.000639	0.00228	CcSEcCtD
Dihydroergotamine—Headache—Ezetimibe—atherosclerosis	0.000637	0.00228	CcSEcCtD
Dihydroergotamine—Pruritus—Niacin—atherosclerosis	0.00063	0.00225	CcSEcCtD
Dihydroergotamine—Asthenia—Pravastatin—atherosclerosis	0.000629	0.00225	CcSEcCtD
Dihydroergotamine—Pruritus—Pravastatin—atherosclerosis	0.00062	0.00222	CcSEcCtD
Dihydroergotamine—Vomiting—Simvastatin—atherosclerosis	0.000616	0.0022	CcSEcCtD
Dihydroergotamine—Nausea—Lovastatin—atherosclerosis	0.000616	0.0022	CcSEcCtD
Dihydroergotamine—Rash—Simvastatin—atherosclerosis	0.000611	0.00218	CcSEcCtD
Dihydroergotamine—Dermatitis—Simvastatin—atherosclerosis	0.000611	0.00218	CcSEcCtD
Dihydroergotamine—Diarrhoea—Niacin—atherosclerosis	0.000609	0.00218	CcSEcCtD
Dihydroergotamine—Headache—Simvastatin—atherosclerosis	0.000607	0.00217	CcSEcCtD
Dihydroergotamine—Nausea—Ezetimibe—atherosclerosis	0.000604	0.00216	CcSEcCtD
Dihydroergotamine—Diarrhoea—Pravastatin—atherosclerosis	0.0006	0.00214	CcSEcCtD
Dihydroergotamine—Dizziness—Niacin—atherosclerosis	0.000589	0.0021	CcSEcCtD
Dihydroergotamine—Dizziness—Pravastatin—atherosclerosis	0.00058	0.00207	CcSEcCtD
Dihydroergotamine—Nausea—Simvastatin—atherosclerosis	0.000576	0.00206	CcSEcCtD
Dihydroergotamine—Vomiting—Niacin—atherosclerosis	0.000566	0.00202	CcSEcCtD
Dihydroergotamine—Rash—Niacin—atherosclerosis	0.000561	0.00201	CcSEcCtD
Dihydroergotamine—Dermatitis—Niacin—atherosclerosis	0.000561	0.002	CcSEcCtD
Dihydroergotamine—Headache—Niacin—atherosclerosis	0.000558	0.00199	CcSEcCtD
Dihydroergotamine—Vomiting—Pravastatin—atherosclerosis	0.000557	0.00199	CcSEcCtD
Dihydroergotamine—Rash—Pravastatin—atherosclerosis	0.000553	0.00197	CcSEcCtD
Dihydroergotamine—Dermatitis—Pravastatin—atherosclerosis	0.000552	0.00197	CcSEcCtD
Dihydroergotamine—Headache—Pravastatin—atherosclerosis	0.000549	0.00196	CcSEcCtD
Dihydroergotamine—Nausea—Niacin—atherosclerosis	0.000529	0.00189	CcSEcCtD
Dihydroergotamine—Nausea—Pravastatin—atherosclerosis	0.000521	0.00186	CcSEcCtD
Dihydroergotamine—HTR1B—artery—atherosclerosis	0.000159	0.155	CbGeAlD
Dihydroergotamine—HTR1D—artery—atherosclerosis	0.000154	0.15	CbGeAlD
Dihydroergotamine—HTR1B—blood vessel—atherosclerosis	0.000124	0.121	CbGeAlD
Dihydroergotamine—HTR1D—blood vessel—atherosclerosis	0.00012	0.117	CbGeAlD
Dihydroergotamine—HTR1D—connective tissue—atherosclerosis	6.16e-05	0.0599	CbGeAlD
Dihydroergotamine—HTR1B—cardiovascular system—atherosclerosis	5.53e-05	0.0538	CbGeAlD
Dihydroergotamine—HTR1D—cardiovascular system—atherosclerosis	5.36e-05	0.0521	CbGeAlD
Dihydroergotamine—HTR2B—cardiovascular system—atherosclerosis	4.98e-05	0.0485	CbGeAlD
Dihydroergotamine—HTR1A—cardiovascular system—atherosclerosis	4.47e-05	0.0434	CbGeAlD
Dihydroergotamine—HTR2B—adipose tissue—atherosclerosis	4.39e-05	0.0428	CbGeAlD
Dihydroergotamine—ABCB1—blood vessel—atherosclerosis	3.91e-05	0.038	CbGeAlD
Dihydroergotamine—ADRA2A—connective tissue—atherosclerosis	3.6e-05	0.035	CbGeAlD
Dihydroergotamine—ADRA2A—adipose tissue—atherosclerosis	2.76e-05	0.0268	CbGeAlD
Dihydroergotamine—ADRA2A—Metabolism—HMOX1—atherosclerosis	2.56e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CETP—atherosclerosis	2.56e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—FABP4—atherosclerosis	2.55e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LCAT—atherosclerosis	2.55e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CAV1—atherosclerosis	2.55e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL5—atherosclerosis	2.55e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CG—atherosclerosis	2.55e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOA1—atherosclerosis	2.54e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CG—atherosclerosis	2.53e-05	0.000162	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	2.51e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CG—atherosclerosis	2.51e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA4—atherosclerosis	2.51e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LPL—atherosclerosis	2.49e-05	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CG—atherosclerosis	2.47e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—MAPK3—atherosclerosis	2.47e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP7A1—atherosclerosis	2.46e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ESR1—atherosclerosis	2.46e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOB—atherosclerosis	2.45e-05	0.000157	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SCARB1—atherosclerosis	2.45e-05	0.000157	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—MAPK3—atherosclerosis	2.44e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—F2—atherosclerosis	2.43e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	2.42e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—MAPK3—atherosclerosis	2.42e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—INS—atherosclerosis	2.41e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TGFB1—atherosclerosis	2.4e-05	0.000154	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KNG1—atherosclerosis	2.39e-05	0.000154	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—INS—atherosclerosis	2.39e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTM1—atherosclerosis	2.39e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGTR1—atherosclerosis	2.38e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL2—atherosclerosis	2.37e-05	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	2.37e-05	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SPP1—atherosclerosis	2.36e-05	0.000151	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL2—atherosclerosis	2.35e-05	0.000151	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	2.35e-05	0.000151	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—INS—atherosclerosis	2.34e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—LPL—atherosclerosis	2.34e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL2—atherosclerosis	2.33e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF1—atherosclerosis	2.33e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CG—atherosclerosis	2.32e-05	0.000149	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PLG—atherosclerosis	2.32e-05	0.000149	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMGCR—atherosclerosis	2.31e-05	0.000149	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF1—atherosclerosis	2.31e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL2—atherosclerosis	2.3e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GPX1—atherosclerosis	2.28e-05	0.000147	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.27e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	2.27e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1—atherosclerosis	2.26e-05	0.000145	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—MAPK3—atherosclerosis	2.23e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CD36—atherosclerosis	2.22e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SERPINE1—atherosclerosis	2.21e-05	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—INS—atherosclerosis	2.2e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	2.2e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	2.2e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	2.18e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL2—atherosclerosis	2.16e-05	0.000139	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.16e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA2—atherosclerosis	2.16e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.16e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.16e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	2.15e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AGT—atherosclerosis	2.13e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.13e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1—atherosclerosis	2.13e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	2.12e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOS3—atherosclerosis	2.11e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	2.11e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—atherosclerosis	2.11e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOS3—atherosclerosis	2.1e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—atherosclerosis	2.09e-05	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—atherosclerosis	2.09e-05	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CAV1—atherosclerosis	2.07e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARA—atherosclerosis	2.07e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOA1—atherosclerosis	2.06e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ABCA1—atherosclerosis	2.06e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPA—atherosclerosis	2.06e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOS3—atherosclerosis	2.05e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOB—atherosclerosis	2.05e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	2.03e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—atherosclerosis	2.02e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	2.02e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AGT—atherosclerosis	2e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	2e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ESR1—atherosclerosis	1.99e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—BGN—atherosclerosis	1.99e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA5—atherosclerosis	1.97e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—F2—atherosclerosis	1.97e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—atherosclerosis	1.96e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LPL—atherosclerosis	1.96e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CAV1—atherosclerosis	1.94e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOA1—atherosclerosis	1.94e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—atherosclerosis	1.93e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	1.9e-05	0.000122	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.9e-05	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	1.88e-05	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—atherosclerosis	1.87e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	1.86e-05	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	1.85e-05	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	1.85e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.83e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	1.82e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	1.81e-05	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	1.8e-05	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	1.8e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INS—atherosclerosis	1.78e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—atherosclerosis	1.78e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—atherosclerosis	1.77e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—atherosclerosis	1.77e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—atherosclerosis	1.77e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	1.76e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—atherosclerosis	1.75e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—ABCB1—cardiovascular system—atherosclerosis	1.74e-05	0.017	CbGeAlD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—atherosclerosis	1.73e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—atherosclerosis	1.73e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	1.72e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	1.71e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—atherosclerosis	1.71e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOB—atherosclerosis	1.7e-05	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—atherosclerosis	1.7e-05	0.000109	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—atherosclerosis	1.68e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NFKB1—atherosclerosis	1.68e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—INS—atherosclerosis	1.68e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	1.67e-05	0.000107	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—atherosclerosis	1.67e-05	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	1.66e-05	0.000107	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	1.65e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—atherosclerosis	1.65e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK8—atherosclerosis	1.65e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—atherosclerosis	1.65e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.64e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—atherosclerosis	1.64e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	1.64e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	1.64e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	1.64e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	1.64e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LIPC—atherosclerosis	1.63e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	1.63e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	1.63e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—atherosclerosis	1.63e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	1.63e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOC3—atherosclerosis	1.62e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	1.62e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—LPL—atherosclerosis	1.62e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LDLR—atherosclerosis	1.61e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	1.6e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	1.6e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—atherosclerosis	1.58e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CETP—atherosclerosis	1.58e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	1.57e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—atherosclerosis	1.56e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—atherosclerosis	1.55e-05	9.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—F2—atherosclerosis	1.55e-05	9.93e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CD36—atherosclerosis	1.54e-05	9.87e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—adipose tissue—atherosclerosis	1.54e-05	0.015	CbGeAlD
Dihydroergotamine—ADRA2A—Metabolism—ALB—atherosclerosis	1.54e-05	9.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	1.53e-05	9.82e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—liver—atherosclerosis	1.52e-05	0.0148	CbGeAlD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—atherosclerosis	1.52e-05	9.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.51e-05	9.69e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.51e-05	9.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—atherosclerosis	1.51e-05	9.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	1.5e-05	9.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	1.5e-05	9.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1.5e-05	9.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	1.48e-05	9.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	1.48e-05	9.49e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—atherosclerosis	1.47e-05	9.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—atherosclerosis	1.46e-05	9.4e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—atherosclerosis	1.46e-05	9.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK3—atherosclerosis	1.44e-05	9.24e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARA—atherosclerosis	1.43e-05	9.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	1.43e-05	9.17e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.43e-05	9.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	1.42e-05	9.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INS—atherosclerosis	1.4e-05	9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	1.4e-05	8.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—atherosclerosis	1.4e-05	8.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	1.39e-05	8.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	1.39e-05	8.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	1.39e-05	8.9e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AGT—atherosclerosis	1.38e-05	8.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	1.38e-05	8.85e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—atherosclerosis	1.38e-05	8.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	1.36e-05	8.71e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—atherosclerosis	1.36e-05	8.71e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.36e-05	8.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.34e-05	8.63e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAV1—atherosclerosis	1.34e-05	8.63e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—atherosclerosis	1.34e-05	8.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.34e-05	8.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.32e-05	8.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	1.31e-05	8.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.29e-05	8.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	1.28e-05	8.18e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.27e-05	8.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.25e-05	8.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.24e-05	7.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.23e-05	7.89e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.22e-05	7.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.22e-05	7.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.22e-05	7.81e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—atherosclerosis	1.18e-05	7.58e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—INS—atherosclerosis	1.16e-05	7.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.13e-05	7.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.12e-05	7.16e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.09e-05	7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.09e-05	7e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—liver—atherosclerosis	1.08e-05	0.0105	CbGeAlD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.07e-05	6.84e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—atherosclerosis	1.06e-05	6.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.05e-05	6.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—atherosclerosis	1.05e-05	6.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—atherosclerosis	1.04e-05	6.7e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOB—atherosclerosis	1.04e-05	6.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.04e-05	6.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.03e-05	6.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—atherosclerosis	1.02e-05	6.56e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—atherosclerosis	1.02e-05	6.52e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.02e-05	6.52e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPL—atherosclerosis	9.97e-06	6.4e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	9.86e-06	6.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	9.76e-06	6.26e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—atherosclerosis	9.73e-06	6.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—atherosclerosis	9.71e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	9.64e-06	6.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—atherosclerosis	9.61e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	9.59e-06	6.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	9.57e-06	6.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD36—atherosclerosis	9.48e-06	6.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—atherosclerosis	9.44e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—atherosclerosis	9.3e-06	5.97e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—atherosclerosis	8.98e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	8.87e-06	5.69e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	8.86e-06	5.68e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARA—atherosclerosis	8.81e-06	5.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	8.77e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AGT—atherosclerosis	8.53e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	8.38e-06	5.38e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—atherosclerosis	8.36e-06	5.36e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAV1—atherosclerosis	8.28e-06	5.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—atherosclerosis	8.26e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	8.13e-06	5.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—atherosclerosis	7.79e-06	5e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.54e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—atherosclerosis	7.28e-06	4.67e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	7.19e-06	4.61e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—INS—atherosclerosis	7.14e-06	4.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—atherosclerosis	6.76e-06	4.34e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—atherosclerosis	6.55e-06	4.2e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—atherosclerosis	6.26e-06	4.02e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	6.13e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.73e-06	3.68e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	5.65e-06	3.63e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—atherosclerosis	4.67e-06	3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—atherosclerosis	2.88e-06	1.85e-05	CbGpPWpGaD
